DEC 2017
Rhinitis Update 2017
Ann Allergy Asthma Immunol . 2017 Dec;119(6):489-511.e41.
Mark S. Dykewicz, MD; Dana V. Wallace, MD; Fuad Baroody, MD; Jonathan Bernstein, MD; Tim Craig, DO;
Ira Finegold, MD; Faith Huang, MD; Desiree Larenas-Linnemann, MD; Eli Meltzer, MD;
Gary Steven, MD, PhD; David I. Bernstein, MD; Joann Blessing-Moore, MD; Chitra Dinakar, MD;
Matthew Greenhawt, MD, MBA; Caroline C. Horner, MD; David A. Khan, MD; David Lang, MD;
John Oppenheimer, MD; Jay M. Portnoy, MD; Christopher R. Randolph, MD; Matthew A. Rank, MD;
Workgroup Chair and Cochair: Mark S. Dykewicz, MD; Dana V. Wallace, MD
Abstract
Allergic rhinitis (AR) is a prevalent disorder responsible for a significant and often underappreciated health burden for individuals and society (see Burden of Disease section). Guidelines to improve care for patients with AR have been evolving in an effort to respond to the introduction of new treatment approaches, to address the availability of additional studies that compare treatment options, and to incorporate the use of more standardized, evidence-based medicine methods to analyze data and make recommendations. 1 , 2 , 3 , 4 As part of a comprehensive review of recommendations made in an updated practice parameter on rhinitis published in 2008 by the Joint Task Force on Practice Parameters (JTFPP) of the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American College of Allergy, Asthma, and Immunology (ACAAI), and the Joint Council of Allergy, Asthma, and Immunology, a workgroup of the Joint Task Force was convened to develop this focused guideline document on seasonal allergic rhinitis (SAR) treatment. [4] The Treatment of Seasonal Allergic Rhinitis: An Evidence-Based Focused 2017 Guideline Update is the first AAAAI/ACAAI guideline on rhinitis to use the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach with an explicit declaration and management of potential competing interests of panel members.
Click Below to Read the Full Publication